95 results
6-K
EX-1.1
ALVO
Alvotech
14 Jun 24
Cautionary Note Regarding Forward Looking Statements
4:36pm
the Securities Act prior to the first Issuance Notice. The Company will comply to the Commission’s satisfaction with all requests of the Commission … Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially
424B5
ALVO
Alvotech
14 Jun 24
Prospectus supplement for primary offering
4:30pm
relating to satisfaction and discharge of the indenture;
additions to or changes in the provisions relating to the modification of the indenture both
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
9:00am
deficiencies to the satisfaction of the regulators; (10) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (11
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
8:41am
partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its
6-K
EX-99.1
xxwkn5
30 Apr 24
Current report (foreign)
8:00am
6-K
EX-99.1
s66r53j v6w9enozab
25 Apr 24
Current report (foreign)
12:36pm
6-K
EX-99.1
9di8m73z4n76orv3j
19 Apr 24
Current report (foreign)
8:05am
6-K
EX-99.1
j7cocq
16 Apr 24
Current report (foreign)
6:30pm
6-K
EX-99.3
r82zccz
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
acx9 3vqi
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
vq7kwa9d u4k
26 Feb 24
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
7:00am
6-K
EX-99.1
ptt2fiy5b62mia
23 Feb 24
Current report (foreign)
8:39pm
6-K
EX-99.1
4tjio snti35wnorez
29 Jan 24
Current report (foreign)
7:00am
6-K
EX-99.1
yk6y1s6 vfneu3k0
10 Jan 24
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
7:00am
6-K
EX-99.1
8fimsi
3 Jan 24
Current report (foreign)
2:28pm
6-K/A
EX-99.1
g9cqtboso ebxadixbn
30 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
9:19am
6-K
EX-99.1
42jxrdi
29 Nov 23
Current report (foreign)
7:00am
6-K
EX-99.1
clpkq9hrfl9pz baqhf
29 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
7:00am